Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.
about
Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent CytotoxicityAntibody Engineering for Pursuing a Healthier FutureEnhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.Comparative N-Glycosylation Analysis of the Fc Portions of a Chimeric Human Coagulation Factor VIII and Immunoglobulin G1Impact of host cell line choice on glycan profile.One pot synthesis of GDP-mannose by a multi-enzyme cascade for enzymatic assembly of lipid-linked oligosaccharides.Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation.Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies.Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.Variable Domain N-Linked Glycans Acquired During Antigen-Specific Immune Responses Can Contribute to Immunoglobulin G Antibody Stability.Affinity of human IgG subclasses to mouse Fc gamma receptors.Promoter methylation of the MGAT3 and BACH2 genes correlates with the composition of the immunoglobulin G glycome in inflammatory bowel disease.IgG Glyco-Engineering to Improve IVIg Potency
P2860
Q33766365-4A744765-A691-44E0-8A82-59F0B46E4918Q38731632-43A69CB6-EC9B-4B1D-96FF-8D5CE5BA2247Q38752663-55855AD3-46A0-4163-AEB7-8D0C74906DCAQ38912355-3D607B43-4F88-4027-87C2-3056F450E14FQ40077073-E181F098-E211-4178-A079-92382D75142CQ41512058-67A0CEBF-69A1-4DD6-85B9-CFE4C2B530E1Q47269842-FC799DAB-914D-4DD5-A5C5-497D0CAA99D6Q47663331-C72E3829-FE16-4DD5-ACDD-A2DEB23CB9F1Q47700104-B76985F7-5490-4BC1-8695-8976BBBF25A4Q49369660-9A440409-4A4B-4BA7-BAD3-D273EF03DBBDQ53689028-D16D925E-901D-4F5B-93B5-AD73A666C1CCQ55091658-FBAC765E-45ED-4792-9DBC-3185EE5A2A45Q55116109-A79875D6-65C5-4B5F-BDBC-DA480C5F73BAQ55491567-AEAAE7EC-E8FF-4954-AFBD-7A70EE33803DQ58572561-4F5FFB8D-B482-4C6C-A77D-6C8BA9F01E1B
P2860
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.
@en
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.
@nl
type
label
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.
@en
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.
@nl
prefLabel
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.
@en
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.
@nl
P2093
P2860
P50
P356
P1433
P1476
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans
@en
P2093
Carolien A M Koeleman
Hans H von Horsten
Remco Visser
Rosina Plomp
Theo Rispens
Volker Sandig
P2860
P2888
P356
10.1038/SREP36964
P407
P577
2016-11-22T00:00:00Z